2013 BMT Tandem Meetings: BMT Tandem Meetings Best Abstracts

1

Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation
Jacalyn Rosenblatt, MD, Beth Israel Deaconess Medical Center; Irit Avivi, MD, Rambam Medical Center; David Vasir, PhD, Dana Farber Cancer Institute; Lynne Uhl, MD, Beth Israel Deaconess Medical Center; Tami Katz, PhD, Rambam Medical Center; Poorvi Somaiya, Beth Israel Deaconess Medical Center; Heidi Mills, Beth Israel Deaconess Medical Center; Robin Joyce, MD, Beth Israel Deaconess Medical Center; James D Levine, MD, M.S., Beth Israel Deaconess Medical Center; Vassiliki A Boussiotis, MD PhD, Beth Israel Deaconess Medical Center; Katarina Luptakova, MD, Beth Israel Deaconess Medical Center; Jon Arnason, MD, Beth Israel Deaconess Medical Center; Natalie Drummy, RN, Beth Israel Deaconess Medical Center; Carol Delaney, RN, Beth Israel Deaconess Medical Center; Emma Breault, Beth Israel Deaconess Medical Center; Viki Held, PhD, Rambam Medical Center; Lina Bisharat, Rambam Medical Center; Nancy Giallombardo, NP, Beth Israel Deaconess Medical Center; Jamie Mortellite, NP, Beth Israel Deaconess Medical Center; Judith Wagoner, NP, Beth Israel Deaconess Medical Center; Michael Schickler, CureTech, Ltd.; Rinat Rotem-Yehudar, CureTech, Ltd.; Paul G. Richardson, MD, Dana Farber Cancer Institute; Jacob Laubach, MD, Dana Farber Cancer Institute; Kenneth Anderson, MD, Dana Farber Cancer Institute; Nikhil Munshi, MD, Dana Farber Cancer Institute; Jacob Rowe, MD, Rambam Medical Center; Donald Kufe, MD, Dana Farber Cancer Institute; David Avigan, MD, Beth Israel Deaconess Medical Center

2

Targeting Deacetylases As a Novel Strategy for Prevention of Acute Gvhd
Sung Won Choi, M.D., University of Michigan; Guoqing Hou, Ph.D, University of Michigan; Jan H. Beumer, Ph.D, University of Pittsburgh; Isao Tawara, M.D., Ph.D, Mie University Hospital; Yaping Sun, Ph.D., University of Michigan; Thomas Braun, Ph.D., University of Michigan School of Public Health; Lawrence Chang, M.D., M.P.H., University of Michigan; Charles Dinarello, M.D., University of Colorado; James L.M. Ferrara, M.D., D.Sc., University of Michigan; John F. DiPersio, MD, PhD, Washington University School of Medicine; Pavan Reddy, M.D., University of Michigan

3

Inhibition of c-Rel Activity Prevents Graft-Versus-Host Disease without Compromising Tumor Immunity
Yusuke Shono, MD, PhD, Memorial Sloan-Kettering Cancer Center; Andrea Z. Tuckett, PhD, Memorial Sloan-Kettering Cancer Center; Hsiou-Chi Liou, PhD, Weill-Cornell Medical Center; Gregoire Altan-Bonnet, PhD, Memorial Sloan-Kettering Cancer Center; Jennifer J Tsai, MD, Memorial Sloan-Kettering Cancer Center; Odette M Smith, BA, Memorial Sloan-Kettering Cancer Center; Mallory L West, BS, Memorial Sloan-Kettering Cancer Center; Natalie V Singer, BS, Memorial Sloan-Kettering Cancer Center; Marcel R.M. van den Brink*, MD, PhD, Memorial Sloan-Kettering Cancer Center; Johannes L Zakrzewski*, MD, Memorial Sloan-Kettering Cancer Center

4

Improved Survival with Intravenous Busulfan (IV BU) Compared to Total Body Irradiation (TBI)-Based Myeloablative Conditioning Regimens: A Cibmtr Prospective Study
Chris Bredeson, Universtiy of Ottawa; Jennifer Le-Rademacher, PhD, Medical College of Wisconsin; Xiaochun Zhu, CIBMTR; Jeanne Burkart, CIBMTR - Milwaukee; Kazunobu Kato, MD, Otsuka Pharmaceutical Development & Commercialization, Inc.; Elizabeth Armstrong, MS, Otsuka Pharmaceutical Development & Commercialization, Inc.; Yiping Sun, PhD, Otsuka Pharmaceutical Development & Commercialization, Inc.; Angela Smith, MS, PA, Otsuka Pharmaceutical Development & Commercialization, Inc.; Vincent T. Ho, MD, Dana-Farber Cancer Institute; Philip L. McCarthy, MD, Roswell Park Cancer Institute; Kenneth R. Cooke, MD, University Hospitals Case Western Reserve; J. Douglas Rizzo, MD, MS, CIBMTR/Medical College of Wisconsin; Marcelo C. Pasquini, MD, MS, CIBMTR/Medical College of Wisconsin

5

Safety and Clinical Efficacy of Rapidly-Generated Trivirus-Directed T Cells After Allogeneic Hematopoietic Stem Cell Transplant
Ulrike Gerdemann, MD, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital; Usha Katari, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital; Jacqueline Keirnan, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital; Anastasia Papadopoulou, PhD, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital; John Craddock, MD, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital; Hao Liu, PhD, Baylor College of Medicine; Caridad Martinez, MD, Baylor College of Medicine, Texas Children's Hospital; Alana Kennedy-Nasser, MD, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital; Kathryn Leung, MD, Baylor College of Medicine, Texas Children's Hospital; Stephen Gottschalk, MD, Baylor College of Medicine, Texas Children's Hospital; Adrian P. Gee, PhD, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital; Robert A. Krance, MD, Baylor College of Medicine, Texas Children's Hospital; Malcolm K. Brenner, MD, PhD, Baylor College of Medicine, Texas Children's Hospital; Cliona M. Rooney, PhD, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital; Helen E Heslop, MD, Baylor College of Medicine, Texas Children's Hospital; Ann M Leen, PhD, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital

6

Competitive TNF Inhibitor (etanercept) for the Treatment of Idiopathic Pneumonia Syndrome (IPS) Following Allogeneic Stem Cell Transplantation (SCT). A Joint Pediatric Blood and Marrow Transplant Consortium (PBMTC) and Childrens Oncology Group (COG) Study
Gregory Yanik, M.D., University of Michigan; Steve Grupp, MD, PhD, The Children's Hospital of Philadelphia; Michael A. Pulsipher, MD, Primary Children's Medical Center/Huntsman Cancer Institute, University of Utah School of Medicine; John E Levine, M.D., M.S., University of Michigan; Kirk R. Schultz, BC Childrens Hospital; Donna A Wall, MD, CancerCare Manitoba; Bryan Langholz, PhD, Childrens Oncology Group; Christopher C Dvorak, MD, UCSF Benioff Children's Hospital; Keith Alangaden, University of Michigan Medical Center; Kenneth R. Cooke, MD, University Hospitals Case Western Reserve

S-BestAb BMT Tandem Meetings Best Abstracts